Join us this episode for a conversation with Norbert Weidner, MD, Professor and Chair of the Spinal Cord Injury Center at Heidelberg University Hospital. In this conversation we discuss results of a clinical trial called the Neuroimmunophilin Nogo-A Antibody in Spinal Cord Injury (NISCI) trial. Findings from this trial were published in a paper titled "Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial" in the journal Lancet Neurology. In this paper Weidner and the NISCI team discuss the top-line findings from this large multi-center clinical trial where a drug (with antibodies against Nogo-A, a protein found in the walls of spinal cord neurons and their support cells) were given to people early after their accident. We invite you to listen in as Dr. Weidner gives an insider perspective on the NISCI trial, and trust you will enjoy our conversation on new pharmaology in the acute phase of SCI.

Join us this episode for a conversation with Norbert Weidner, MD, Professor and Chair of the Spinal Cord Injury Center at Heidelberg University Hospital. In this conversation we discuss results of the Neuroimmunophilin Nogo-A Antibody in Spinal Cord Injury (NISCI) trial, published in a paper titled "Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial" in the journal Lancet Neurology. In this paper Weidner and their NISCI team discuss the top-line findings from a large multi-center clinical trial where antibodies against Nogo-A were administered to the spinal space early after acquired SCI. We invite you to listen in as Dr. Weidner gives an insider perspective on the NISCI trial, and trust you will enjoy our conversation on intrathecal drug delivery in the acute phase of SCI.

Join us in this episode for a conversation with Jen French and Ian Burkhart, leaders of neurotech development movements and users of implanted neurological devices. Our guests share briefly about their experience with implanted devices, and then the conversation zooms in on exciting recently developments in implantable brain-computer interface (iBCI) and electrical simulation options such as epidural spinal cord stimulation (eSCS). Having been through the process, Jen and Ian deliberate on the importance and steps in engaging people with the lived-experience of paralysis in the development of meaningful clinical outcome assessments for clinical trials. Safety and aversion to electing for implantation are also discussed. We hope you enjoy this episode with Jen French and Ian Burkhart on these exciting neurological technologies and the role of lived-experience in neurotech now and in the future.